At first glance, the 2027 Medicare Advantage Star Ratings tell two different stories. Contracts earning four or more Stars fell from 44% in 2026 to 37% in 2027. Yet the share of beneficiaries enrolled in those contracts rose from 67% to 71%. Contracts with higher concentrations of employer group members also tended to outperform those with little or no EGWP enrollment.
Contract structure, member populations, and financial exposure shape what a Star Rating actually signals. “Knowing the results and understanding what they actually signal are two very different things,” said Kimberly Switlick-Prose, Vice President, Quality & Member Solutions at Pareto Intelligence.
During Pareto’s recent webinar, Beyond the Noise: Insights from the 2027 Star Ratings & Implications for Health Plans, Kimberly joined Damian Kearney, Pareto’s Vice President of Analytics, and Andrew Bell, Managing Director at ProspHire, to examine what’s driving the results and what health plans should consider next.
Bigger contracts, better ratings, and more to lose
Just 20 of the 508 scored Medicare Advantage Prescription Drug (MAPD) contracts account for nearly half of the market’s enrollment. These contracts, each with more than 350,000 members, averaged 4.23 Stars, compared with 3.75 Stars for the other 488 contracts.
The difference is also striking when looking at enrollment. Approximately 93% of members in the largest contracts are enrolled in four-plus-star contracts, compared with 49% in smaller contracts.

Large health plans benefit from greater influence over provider networks and more resources to reinvest in quality and member experience. National carriers can offset weaker performance in one market with stronger results elsewhere. But concentrating millions of members in a single contract also concentrates financial exposure when ratings fall.
Regional plans have less flexibility to offset performance gaps, but they often benefit from closer provider relationships, deeper market knowledge, and greater agility.
Geography is another aspect. Pareto’s analysis found that contracts with higher rural enrollment generally performed worse overall, though the differences varied by measure. More urban contracts tended to perform better on clinical measures, while those with higher rural enrollment showed advantages in some patient-experience and Health Outcomes Survey (HOS) measures.
The takeaway: A Star Rating is not just a measure of performance. It reflects how a plan is built, whom it serves, and how much financial risk sits behind the number.
Member population changes the performance equation
Differences in performance are even more pronounced when comparing Special Needs Plans (SNPs) with traditional Medicare Advantage contracts. Approximately 78% of members in non-SNP contracts were enrolled in four-plus-star contracts for 2027, compared with about 20% in D-SNP-only contracts.
D-SNP members often have more complex medical and behavioral health needs, along with social circumstances that can complicate care coordination.
Pareto’s analysis identified substantial gaps between D-SNP-only and non-SNP contracts across several clinical measures, including polypharmacy, breast cancer screening, readmissions, and medication adherence.
The findings also revealed an important distinction: D-SNP contracts don’t underperform across the board. In fact, D-SNPs outperformed non-SNP contracts on several measures, including Reducing the Risk of Falling, Rating of Health Plan, Rating of Drug Plan, and Monitoring Physical Activity.
These differences underscore why health plans need to look beyond overall ratings to understand what’s driving performance within specific populations. Which performance gaps are most significant? What are the characteristics of the populations served? Which improvement strategies align with those realities?
Why getting better may not improve your Star Rating
Changes to the scoring methodology made it more difficult to achieve higher ratings in 2027.
Every year, Star performance is affected by two factors: changes to the measures and their weights, and changes to the cut points that determine how performance translates into Stars. Both played a role for 2027.
The most significant change to the measure set was increasing the weight of two HOS measures from one to three. Because these measures generally have lower performance scores than many others in the Star Ratings program, the higher weight created additional pressure for numerous contracts. The aggregate impact was relatively modest, though a small number of large contracts benefited from the weighting changes.
Cut points had a broader effect. According to Pareto’s analysis, 86% either increased or stayed the same, compared with 82% the previous year. The largest changes involved Medication Adherence for Diabetes, Controlling Blood Pressure, and Kidney Health Evaluation.
Improving actual performance may not translate into a higher Star Rating when the thresholds for success keep moving.
A half-Star can change the economics of a contract
Star Ratings influence two key Medicare Advantage revenue mechanisms: quality bonus payments and rebates. Crossing the four-star threshold can increase funding available to support benefits and enhance product competitiveness.
The 2027 results provide a dramatic example. Humana’s largest contract improved from 3.5 to four Stars. It covers approximately 2.4 million members, representing 7% of the scored MAPD market. During the webinar, Damian illustrated the potential financial impact using estimated payment assumptions.
Moving from 3.5 to four Stars could increase revenue by about $40 per member per month. Across 2.4 million members, that would translate to roughly $1.2 billion in additional annual revenue, which could be directed toward product design and benefits. The estimate is illustrative, not a report on actual financial results. It demonstrates the scale of the opportunity.
The reverse is just as significant. A large contract falling below four Stars can undermine a carrier’s ability to maintain competitive benefits and support long-term growth.
Overlapping multiyear cycles complicate the picture. Today’s quality performance can affect product development and revenue years into the future. That’s why Star performance needs to be integrated into financial forecasting, product planning, and business strategy.
The next wave of Star Ratings changes could have greater impact
While the 2027 results pose challenges, upcoming changes could make achieving high ratings more difficult. CMS has announced changes to the measure set that will remove several operational measures over the next two Star years.
Call center measures are scheduled for removal for Star Year 2028. Other operational measures, including those related to complaints, appeals, and disenrollment, are scheduled for removal in Star Year 2029. Removing these measures increases the relative influence of clinical and patient-reported measures, which are often tougher to improve.

Pareto modeled the potential impact of these known measure changes. The findings are striking. If the anticipated changes to the measure were applied to current performance, the percentage of contracts achieving four or more Stars could decline from 37% to about 28%.
Assuming today’s enrollment distribution remains constant, the percentage of beneficiaries in four-plus-star contracts could decline from about 71% to 53%.
These are modeled projections, not predictions of future ratings. Plans will continue to improve performance, enrollment will change, and other factors may influence the outcome. The analysis illustrates the potential impact of removing measures that currently support higher overall ratings.
Legal challenges add another layer of uncertainty
Legal challenges to the Star Ratings methodology have already prompted scoring adjustments, with the Clover Health litigation drawing particular attention. After a federal court ruling on Clover’s 2026 ratings, CMS recalculated scores using a revised approach. Subsequent appeals and additional litigation have raised questions about how future ratings may be affected.
Plans need strategies that can adapt to changes without losing focus on sustainable performance improvement.
Three moves to turn Star results into strategy
The webinar’s central message was that Star Ratings management must move beyond tracking metrics and responding to annual scoring changes. Success requires integrating quality performance, analytics, contract design, and financial planning.
Andrew emphasized that how health plans organize their business is a critical part of the equation. “What decided who won and who lost this year was largely around how these plans are structured, how they’re built.” He also encouraged Star leaders to take a more active role in decisions traditionally made elsewhere in the organization, particularly those related to products, markets, and contract structure.
The webinar highlighted three priorities for health plans:
- Bring Star leaders into strategic planning. Star teams understand how contracts, populations, and markets affect performance. Their insights can guide decisions on geographic expansion, contract consolidation, and product strategy.
- Focus improvement efforts where they matter most. Damian encouraged plans to prioritize highly weighted measures with meaningful opportunities for improvement. Rather than targeting four or five Stars on every measure, use realistic benchmarks, population characteristics, and remaining opportunities for improvement to prioritize resources.
- Prepare for changes before they affect ratings. Model the impact of upcoming measure changes, assess exposure to the four-star threshold, and align quality improvement priorities with future scoring requirements. Keep finance and executive leadership informed of potential revenue implications.
“What the data are showing is that the Star system is getting much harder,” noted Damian. Waiting until those effects appear in a contract’s overall rating can leave health plans with fewer options and less time to respond.
Moving beyond the numbers
The 2027 Star Ratings results show that national averages and annual score changes don’t tell the whole story. Scale, contract structure, member populations, measure weighting, and financial exposure all influence how those results apply to individual health plans.
Health plans can’t control every change in scoring methodology or predict every legal outcome. They can use data to assess their position, identify improvement opportunities, and align quality performance with broader business strategy.
There’s more to the 2027 Star Ratings than the headline numbers.
Explore Pareto’s analysis and hear expert perspectives on the trends, risks, and opportunities ahead. Watch the on-demand webinar Beyond the Noise: Insights from the 2027 Star Ratings & Implications for Health Plans.